Tegafur Tablets
Function and Efficacy
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of the anti-pyrimidine class. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No serious bone marrow suppression was observed in the chronic toxicity experiment, and the effect on immunity was relatively mild.
Ingredients
1-(Tetrahydro-2-furyl)-5-fluoro-2,4(1H,3H)-pyrimidinedione.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| TegafurIngredients |
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of the anti-pyrimidine class. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No serious bone marrow suppression was observed in the chronic toxicity experiment, and the effect on immunity was relatively mild. More |
17902-23-7 | 10 |
Appearance
This product is white tablets.
Indication
It is mainly used to treat digestive tract tumors, and has certain effects on gastric cancer, colon cancer, and rectal cancer. It can also be used to treat breast cancer, bronchial lung cancer, liver cancer, etc. It can also be used for bladder cancer, prostate cancer, kidney cancer, etc.
Usage and Dosage
Oral administration: 0.2-0.4g per time, 0.6-1.2g per day. A total of 20-40g per course of treatment. Intravenous injection: 1g per day. The dosage for children is 4-6mg/kg per time, 4 times a day.
Adverse Reactions
Mild bone marrow suppression is manifested by leukopenia and thrombocytopenia. Mild gastrointestinal reactions are mainly loss of appetite and nausea. Some patients may experience vomiting, diarrhea and abdominal pain, which may disappear after stopping the drug. Other reactions include fatigue, chills, fever, headache, dizziness, movement disorders, skin itching, pigmentation, mucositis and vascular pain at the injection site.
Precautions
It is contraindicated for use by pregnant and lactating women.
Special Population Medication
Precautions for children: This product has not been tested and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: This product has not been tested and there is no reliable reference.
Drug Interactions
Tegafur is alkaline and contains carbonate. Avoid using it with drugs containing calcium or magnesium ions or with strong acidity.
Storage
Keep away from light, tightly closed, in a cool place.
Packaging Specification
50mg
Validity Period
24 months